Immunoconjugates for treating diseases associated with neovascularization
such as cancer, rheumatoid arthritis, the exudative form of macular degeneration,
and atherosclerosis are described. The immunoconjugates typically consist of the
Fc region of a human IgG1 immunoglobulin including the hinge, or other effector
domain or domains that can elicit, when administered to a patient, a cytolytic
immune response or cytotoxic effect against a targeted cell. The effector domain
is conjugated to a targeting domain which comprises a factor VII mutant that binds
with high affinity and specificity to tissue factor but does not initiate blood
clotting such as factor VII having a substitution of alanine for lysine-341 or
of alanine for serine-344.
